Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2025. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at 1:50 pm ET and conduct investor meetings throughout the day.
The presentation will be accessible via webcast at the scheduled time and will subsequently be available in the Investors section of the company's website.
Krystal Biotech (NASDAQ: KRYS), un'azienda biotecnologica in fase commerciale, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston il 4 marzo 2025. Krish S. Krishnan, Presidente e Amministratore Delegato, parteciperà a una chiacchierata informale alle 13:50 ET e condurrà incontri con gli investitori durante tutta la giornata.
La presentazione sarà accessibile tramite webcast all'orario programmato e sarà successivamente disponibile nella sezione Investitori del sito web dell'azienda.
Krystal Biotech (NASDAQ: KRYS), una compañía de biotecnología en etapa comercial, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen en Boston el 4 de marzo de 2025. Krish S. Krishnan, Presidente y Director Ejecutivo, participará en una charla informal a la 1:50 p.m. ET y llevará a cabo reuniones con inversionistas durante todo el día.
La presentación será accesible a través de un webcast en el horario programado y estará disponible posteriormente en la sección de Inversores del sitio web de la compañía.
크리스탈 바이오텍 (NASDAQ: KRYS), 상업 단계의 생명공학 회사가 2025년 3월 4일 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다. 크리쉬 S. 크리쉬난, 회장 겸 CEO는 오후 1시 50분 ET에 화상 대화에 참여하고 하루 종일 투자자 회의를 진행할 예정입니다.
프레젠테이션은 예정된 시간에 웹캐스트를 통해 접근 가능하며, 이후 회사 웹사이트의 투자자 섹션에서 확인할 수 있습니다.
Krystal Biotech (NASDAQ: KRYS), une entreprise de biotechnologie en phase commerciale, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston le 4 mars 2025. Krish S. Krishnan, Président et Directeur Général, participera à une discussion informelle à 13h50 ET et mènera des réunions avec des investisseurs tout au long de la journée.
La présentation sera accessible via un webcast à l'heure prévue et sera ensuite disponible dans la section Investisseurs du site Web de l'entreprise.
Krystal Biotech (NASDAQ: KRYS), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston am 4. März 2025 bekannt gegeben. Krish S. Krishnan, Vorsitzender und CEO, wird um 13:50 Uhr ET an einem Fireside-Chat teilnehmen und den ganzen Tag über Investorenmeetings durchführen.
Die Präsentation wird zur geplanten Zeit über einen Webcast zugänglich sein und anschließend im Investorenbereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
PITTSBURGH, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:50 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 1:50 pm ET on Tuesday, March 4, 2025 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
When is Krystal Biotech (KRYS) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Krystal Biotech's (KRYS) TD Cowen Conference presentation?
Who will represent Krystal Biotech (KRYS) at the 2025 TD Cowen Healthcare Conference?
What type of presentation will KRYS deliver at the TD Cowen Conference 2025?
